November 5, 2025 Third-Quarter 2025 Earnings Update Safe Harbor Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distr ...

Third Quarter 2025 Financial Results Presentation November 5, 2025 Find, mine and deliver the planet's most important and essential minerals that enable the world and humankind to create, innovate, and prosper. N o v e m b e r 2 0 2 5 Forward-Looking Information This presentation contains "forward-looking information" and "forward-looking statements", as defined in applicable securities laws (collectively, "forward- looking statements") including the Private Securities Litigation Reform Act of 1995 which in ...

Q3 2025 Performance Highlights - Sales for Q3 2025 were $807 million, a decrease of 1.1% as reported, but a decline of 2.9% organically (excluding foreign exchange impact)[8] - Adjusted EBITDA for Q3 2025 was $133 million, a 2.2% increase as reported, and a 0.5% increase organically[8] - Adjusted EPS for Q3 2025 was $0.70, a 7.7% increase as reported, and a 4.5% increase excluding foreign exchange[8] - Avient paid down $100 million in debt during the quarter and is on track to repay a total of $150 million for FY 2025[9] Segment Performance - Color, Additives & Inks sales decreased by 1% as reported and 3% organically to $510 million, with an adjusted EBITDA margin of 18.9%[15] - Specialty Engineered Materials sales increased by 1% as reported but decreased by 1% organically to $298 million, with an adjusted EBITDA margin of 19.9%[18] Regional Performance - In Q3 2025, organic revenue growth varied by region: US & Canada decreased by 5%, Europe, Middle East & Africa decreased by 3%, Asia decreased by 1%, and Latin America increased by 1%[20] Full Year 2025 Guidance - Adjusted EBITDA for full year 2025 is projected to be $540 million to $550 million, representing a 3% to 5% growth[24] - Adjusted EPS for full year 2025 is projected to be $2.77 to $2.87, representing a 4% to 8% growth[25]

Q3 2025 Financial Performance - Total revenue reached $1622 million, reflecting a 14% increase excluding the confidential contract [8, 12] - Organic revenue growth, excluding the confidential contract, was 9% [7, 15] - Adjusted EBITDA margin expanded by 60 basis points to 98% [7, 13] - Cash flow from operations amounted to $163 million, with a free cash flow conversion of 135% [7, 8] - The book-to-bill ratio was 10x, maintaining a trailing 12-month ratio of 10x or greater since the IPO [7, 8] Segment Performance - Critical Infrastructure revenue increased by 18% to $833 million, with adjusted EBITDA margin expanding by 360 basis points to 103% [17] - Federal Solutions revenue decreased by 29% to $789 million, with adjusted EBITDA margin decreasing by 170 basis points to 92% [19] Contract Wins and Backlog - The company secured four contract wins exceeding $100 million in Q3 2025 [10] - Backlog increased by $48 million to $88 billion, with 72% being funded [10] - The company has approximately $11 billion worth of contract wins not yet included in the backlog [10] Fiscal Year 2025 Guidance - The company is modifying its FY25 revenue outlook to $64 billion - $65 billion, representing a -4% growth and -8% organically, but reiterating adjusted EBITDA guidance of $600 million - $630 million and cash flow guidance at the mid-point [7, 36]

Financial Status & Outlook - Recursion had approximately $785 million in cash as of October 9, 2025 [12, 72] - The company anticipates a cash runway through the end of 2027 without needing additional financing [12, 71] - Recursion projects its 2025 cash burn to be less than $450 million [73] - The company expects its 2026 cash burn to be less than $390 million [73] - Total cash inflows exceeding $500 million have been achieved across all partnerships and collaborations [15, 72] Pipeline & Platform Advancements - The company is anticipating multiple catalysts in the second half of 2025, including additional safety and efficacy data for REC-4881 in Familial Adenomatous Polyposis (FAP) [11, 79] - Recursion's platform has facilitated a $30 million milestone payment for delivering a second whole-genome neuro map [15, 72, 77] - In a Phase 1b/2 trial of REC-4881, 43% median reduction in total polyp burden was observed [61] - 6 out of 6 patients achieved >30% reduction in total polyp burden in REC-4881 Phase 1b/2 trial [62] - In Phase 1 monotherapy dose-escalation of REC-617, 90% of patients experienced treatment-related adverse events (TRAEs), with 28% being Grade ≥3 [48]

The best-performing financial services group in the Nordics Capital Markets Day 5 November 2025 1 Disclaimer 2 • Nordea and its businesses are exposed to various risks and uncertainties. • This presentation contains certain statements which are not historical facts, including, without limitation, statements communicating expectations regarding, among other things, the results of operations and the bank's financial condition, liquidity, prospects, growth and strategies; and statements preceded by "believes", ...

Financial Performance & Strategic Aspirations - For the first nine months of 2025, Novo Nordisk reported sales growth of 15% at Constant Exchange Rates (CER)[11] - Operating profit growth was 10% at CER, impacted by restructuring costs of 9 billion DKK[11, 68] - The company anticipates annualised savings of approximately 8 billion DKK for reinvestment in future growth[17] - Novo Nordisk is transforming with aim to meet future patient needs and allow for investment in growth opportunities[16] Market & Therapeutic Focus - Obesity care sales reached 59.9 billion DKK, reflecting a 41% increase at CER[11] - Rare disease sales amounted to 14.3 billion DKK, a 13% increase at CER[11] - Diabetes value market share stood at 31.6%, a decrease of 2.3 percentage points[11] - The company aims to strengthen its diabetes leadership, targeting a global value market share exceeding one-third[72] Pipeline & Innovation - Novo Nordisk is progressing its pipeline, including US approval for Rybelsus® CV indication and Wegovy® MASH indication[11] - The company agreed to acquire Akero, including a phase 3 MASH asset, and proposed the acquisition of Metsera, Inc for up to 10 billion USD[11, 47] - Cagrilintide 2.4 mg will be investigated in RENEW phase 3 programme with potential to be the first amylin on the market[58]

Cytisinicline Overview - Cytisinicline represents a potential new treatment for nicotine dependence in nearly 20 years, targeting an addressable market of up to 50 million Americans who use tobacco[7] - The FDA's PDUFA date for cytisinicline for smoking cessation is expected on June 20, 2026[9] - Nicotine dependence is a significant public health crisis, costing billions of dollars[7] Clinical Trial Results - Smoking cessation trials (ORCA-2 and ORCA-3) demonstrated robust efficacy, excellent tolerability, and significant craving reduction[30] - In 12-week cytisinicline treatment trials, quit rates reached 32.6% compared to 7% with placebo, yielding an odds ratio of 6.3 (p<0.0001)[31] - In 6-week cytisinicline treatment trials, quit rates reached 25.3% compared to 4.4% with placebo, yielding an odds ratio of 8.0 (p<0.0001)[31] - Cytisinicline shows a more favorable adverse event profile compared to Varenicline (Chantix®), with lower rates of nausea (6.2% vs 30%), insomnia (10.8% vs 18%), abnormal dreams (7.7% vs 13%), and headache (8.1% vs 15%)[37] Market and Commercial Strategy - Over $600 billion is spent annually in the U S on smoking-related health care costs[14] - Approximately 29 million U S smokers have few treatment options[15] - The company estimates an $11 billion Rx opportunity in the smoking cessation market[57]

KPN Strategy Update | November 5, 2025 Connect Activate Grow Agenda 2 | KPN Strategy Update | November 2025 1. Progress so far 2. Infrastructure Value: Driving connected asset value 3. Transformation Value: Activating the change engine to deliver strategic value 4. Customer Value: Growing by differentiated offerings to customers 5. Financial Value: Financial framework and outlook 6. Q&A Strengthening Our Position via M&A, strategic partnerships and portfolio expansion 3 | KPN Strategy Update Our Progress | ...

Financial Performance (FY2026 First Half) - Operating income decreased to 20056 billion yen, a decrease of 4585 billion yen year-over-year[16] - Net income attributable to Toyota Motor Corporation decreased to 17734 billion yen[16] - Sales revenue increased to 246307 billion yen, an increase of 13483 billion yen[16] Vehicle Sales (FY2026 First Half) - Total retail vehicle sales reached 5643 thousand units, a 50% increase year-over-year[12] - Toyota and Lexus vehicle sales increased to 5267 thousand units, a 47% increase year-over-year[12] - Electrified vehicle sales accounted for 469% of total retail vehicle sales[12] FY2026 Forecast - The new forecast for sales revenues is 49 trillion yen, an increase of 500 billion yen from the previous forecast[40] - The new forecast for operating income is 34 trillion yen, an increase of 200 billion yen from the previous forecast[40] - The forecast for Toyota and Lexus vehicle sales is 105 million units, a 10% increase from the previous forecast[37] Shareholder Returns - The interim dividend is 45 yen per share, an increase of 5 yen year-over-year[6] - The full-year dividend forecast is 95 yen per share, an increase of 5 yen year-over-year[6]